Ellen Donnelly

Amministratore Delegato presso ABLIVA AB

50 anni

Health Technology

Consumer Services

Finance

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Eskil Elmér	M	54	ABLIVA AB	24 anni
Viktor Drvota	M	59	MODUS THERAPEUTICS HOLDING AB Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	8 anni
John Öhd	M	53	MODUS THERAPEUTICS HOLDING AB Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	6 anni
Catharina Jz Johansson	F	57	ABLIVA AB	11 anni
Johan Sandin	M	54	ALZECURE PHARMA AB	8 anni
David Laskow-Pooley	M	70	ABLIVA AB	8 anni
Torsten Rüdiger Goesch	M	65	MODUS THERAPEUTICS HOLDING AB Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	10 anni
David Bejker	M	49	ABLIVA AB	7 anni
Ragnar Linder	M	71	ALZECURE PHARMA AB	7 anni
Eva Lilienberg	F	68	ALZECURE PHARMA AB	3 anni
Mikael Widell	M	-	ALZECURE PHARMA AB	-
Denise Goode	F	66	ABLIVA AB	6 anni
Jan Birger Fredrik Toernell	M	64	ABLIVA AB	7 anni
Martin Jönsson	M	56	ALZECURE PHARMA AB	4 anni
Bror Thomas Pollare	M	71	ALZECURE PHARMA AB	7 anni
Johan Dighed	M	51	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	-
Janet Hoogstraate	M	57	ALZECURE PHARMA AB	1 anni
Eleonor Asander Frostner	F	43	ABLIVA AB	13 anni
Magnus Hansson	M	48	ABLIVA AB	16 anni
Birgitta Lundvik	F	57	ALZECURE PHARMA AB	7 anni
Märta Segerdahl	M	68	ALZECURE PHARMA AB	3 anni
Erik Aksel Bork	M	42	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	3 anni
Joakim Notö	M	-	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	-
Roger Franklin	M	45	ABLIVA AB	4 anni
Claes Lindblad	M	57	MODUS THERAPEUTICS HOLDING AB	3 anni
Dag Nesse	M	58	ABLIVA AB	1 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Gunnar Magnus Modee Persson	M	64	ABLIVA AB	2 anni
Erik Kinnman	M	66	ABLIVA AB	5 anni
An van Es-Johansson	M	64	ALZECURE PHARMA AB	3 anni
Matilda Hugerth	F	49	ABLIVA AB	5 anni
Mats Blom	M	59	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	2 anni
Pirkko Sulila Tamsen	M	65	ALZECURE PHARMA AB	-
Christina Elisabeth Herder	M	63	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	3 anni
Lena Jendeberg	M	60	Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	-

Statistiche

Paese	Relazioni	% del totale
Svezia	34	100.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni